Market Report, "Spain Pharmaceuticals & Healthcare Report Q4 2015", published

From: Fast Market Research, Inc.
Published: Tue Oct 06 2015

Spain's non-transparent and unpredictable government medicine pricing system and the implementation of numerous emergency measures to contain pharmaceutical spending will highly disrupt multinational drugmakers ' strategy and revenue streams. Despite the Spanish economy exiting crisis mode, we believe that the Spanish government will continue to target the healthcare sector - a large recipient of government funds. As a result, we uphold our bearish outlook for the Spanish pharmaceutical market over the next five years.

Headline Expenditure Projections

Pharmaceuticals: EUR23.02bn (USD30.85bn) in 2014 to EUR22.36bn (USD24.60bn) in 2015; -2.9% in local currency terms and -20.3% in US dollar terms. Forecast in line with last quarter.
Healthcare: EUR89.16bn (USD119.47bn) in 2014 to EUR89.51bn (USD98.46bn) in 2015; +0.4% in local currency terms and -17.6% in US dollar terms. Forecast revised downwards from last quarter.

Full Report Details at

Risk/Reward Index

In BMI's Pharmaceutical Risk/Reward Index for Q315, Spain scored 64.2 and ranked 12th out of the 15 countries surveyed in Western Europe - just below the Netherlands (64.7). While Spain offers investors positive features, such as its large drug market, it also has problems, such as the government's focus on cost containment, low population growth, cumbersome bureaucracy and provincial differences regarding drug regulations and reimbursement.

The Spain Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Spain Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Spain pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Spain, to test other views - a key input for successful budgeting and strategic business planning in the Spanish pharmaceutical and healthcare market.
* Target business opportunities and risks in the Spanish pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Spain.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.


BMI Industry View

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »